Mechanism of the hypotensive action of anandamide in anesthetized rats

Hypertension

Volumn 28, Issue 4, 1996, Pages 682-686

  Varga, Karoly ^a,c   Lake, Kristy D ^a   Huangfu, Donghai ^b   Guyenet, Patrice G ^b   Kunos, George ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

cannabinoids; hypotension; receptors, presynaptic; sympathetic nervous system

Indexed keywords

ANANDAMIDE; CANNABINOID; CANNABIS; DRONABINOL; LIGAND; PANCURONIUM BROMIDE; PHENTOLAMINE; PHENYLEPHRINE; TRIMETAPHAN; URETHAN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL REACTIVITY; DENERVATION; DOSE RESPONSE; DRUG MECHANISM; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NERVE CELL EXCITABILITY; NERVE ENDING; NONHUMAN; NORADRENALIN RELEASE; PRESSORECEPTOR REFLEX; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; RAT; SPLANCHNIC NERVE; SYMPATHETIC NERVE;

EID: 0029847296     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.28.4.682     Document Type: Article

References (17)

1. Dewey WL, Harris LS, Howes JF, Kennedy JS, Granchelli FE, Pars HG, Razdan RK. Pharmacology of some marijuana constituents and two heterocyclic analogs. Nature. 1970;226:1255-1257.
2. Hardman HF, Domino EF, Seevers MH. General pharmacological actions of some synthetic tetrahydrocannabinol derivatives. Pharmacol Rev. 1971;23:295-315.
3. Graham JDP, Li DMF. Cardiovascular and respiratory effects of cannabis in cat and rat. Br J Pharmacol. 1973;49:1-10.
4. 9-trans-tetrahydrocannabinol in anesthetized dogs. Res Commun Chem Pathol Pharmacol. 1973;6: 527-540.
5. 9-trans-tetrahydrocannabinol. J Pharm Pharmacol. 1974;26:186-192.
6. Benovitz NL, Jones RT. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther. 1975;25: 440-446.
7. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561-564.
8. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 1993;365:61-65.
9. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson G, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-1949.
10. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrie P, Breliere JC, Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994; 350:240-244.
11. Varga K, Lake K, Martin BR, Kunos G. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol. 1995;278:279-283.
12. 2Adrenoceptor-mediated modulation of bulbospinal barosensitive cells of rat rostral medulla. Am J Physiol. 1993;34:R1065-R1075.
13. Adams MD, Earnhardt JT, Martin BR, Dewey WL, Razdan RK. A cannabinoid with cardiovascular activity but no overt behavioral effects. Experientia. 1977;33:1204-1205.
14. 9-trans-tetrahydrocannabinol in anesthetized dogs. Eur J Pharmacol. 1973;22:263-269.
15. 3H]-(-)-noradrenaline from the isolated vas deferens of the rat. Br J Pharmacol. 1974;52:233-236.
16. Pertwee RG, Stevenson LA, Elrick DB, Mechoulam R, Corbett AD. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol. 1992;105:980-984.
17. Ishac EJN, Jiang L, Lake KD, Varga K, Abood ME, Kunos G. Presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves inhibit exocytotic noradrenaline release. Br J Pharmacol. 1996;118:2023-2028.